COL7A1 and recessive dystrophic epidermolysis bullosa: We have recently achieved the correction of RDEB in epidermal stem cells from patients by using dual-guide CRISPR-Cas9 delivered as RNPs by electroporation into patient keratinocytes to remove exon 80 of COL7A1, the site of a frameshift mutation highly prevalent in the Spanish RDEB population.